Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Anhui Wanbang Pharmaceutical Technology Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Anhui Wanbang Pharmaceutical Technology Co's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Anhui Wanbang Pharmaceutical Technology Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Anhui Wanbang Pharmaceutical Technology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anhui Wanbang Pharmaceutical Technology Co LT-Debt-to-Total-Asset Chart

Anhui Wanbang Pharmaceutical Technology Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Anhui Wanbang Pharmaceutical Technology Co Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial									-	-	-	-	-

Anhui Wanbang Pharmaceutical Technology Co LT-Debt-to-Total-Asset Calculation

Anhui Wanbang Pharmaceutical Technology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	1544.589
	=	0.00

Anhui Wanbang Pharmaceutical Technology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0	/	1568.8
	=	0.00

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Anhui Wanbang Pharmaceutical Technology Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000

Website

http://www.ahwbyy.cn

Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Headlines

No Headlines